Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06343298 · ClinicalTrials.gov registry record · Phase 2

To Evaluate the Safety and Efficacy of MANP in Subjects With Difficult to Control/ Resistant Hypertension

A Phase 2 study of Difficult to Control Hypertension, sponsored by E-Star BioTech.

Recruiting
Registry status
Phase 2
Development phase
120
Enrollment target
20
Study locations

NCT06343298 is a Phase 2 study of Difficult to Control Hypertension that is actively recruiting participants, run by E-Star BioTech. The registered enrollment target is 120 participants. The trial reports 20 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06343298, a Phase 2 study of Difficult to Control Hypertension, is actively recruiting participants, sponsored by E-Star BioTech.

RECRUITING
Registry status
Phase 2
Development phase
120 participants
Enrollment target
20
Study locations

Study Summary

This is a Phase 2 dose-titration study designed to evaluate the safety and efficacy of MANP subcutaneous injection compared to placebo in reducing baseline daytime systolic blood pressure (SBP), derived from 24-hour ambulatory blood pressure monitoring (ABPM), in subjects with hypertension who are taking 3 or more antihypertensive medications with different mechanisms of action.

Interventions

  • DRUG MANP
  • OTHER Placebo Matched control

Study Locations (20)

California

  • Amicis Research Center - Beverly Hills - Beverly Hills
  • Amicis Research Center - Granada Hills - Granada Hills
  • Orange County Research Center - Lake Forest
  • Amicis Research Center - Palmdale - Palmdale
  • Amicis Research Site - Valencia - Valencia
  • Interventional Cardiology Medical Group - West Hills
  • Office of Dr. Edward Portnoy MD - Westlake Village

Florida

  • SM Research Center - Biscayne Park
  • Arrow Clinical Trials - Daytona Beach
  • Royal Research Corp - Hollywood
  • Evolution Clinical Trials - Miami

Georgia

  • Cowry Health - Acworth
  • Alta Pharmaceutical Research Center - Peachtree Corners

Michigan

  • Revival Research Institute, LLC - Dearborn
  • Aa Mrc Llc - Flint

North Carolina

  • Monroe Biomedical Research - Monroe
  • Superior Clinical Research - Smithfield

Arkansas

  • Lynn Institute of the Ozarks - Little Rock

Illinois

  • Cedar Crosse Research Center - Chicago

Ohio

  • K&R Research LLC - Marion

Trial Details

FieldValue
Enrollment Target 120 participants
Start Date 2024-11-17
Est. Completion 2026-09-01
Phase Phase 2

Sponsor

E-Star BioTech

2 total trials

What the Registry Record Tells You About NCT06343298

The ClinicalTrials.gov registry entry for NCT06343298 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is E-Star BioTech, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Difficult to Control Hypertension appearing as the primary indexed condition, and to 2 interventions - of which MANP is the first listed.

NCT06343298 reports 20 study locations spanning 8 distinct geographic areas - top geographies include California, Florida, Georgia.

Frequently Asked Questions

What is clinical trial NCT06343298 about?

NCT06343298 is a clinical study titled "To Evaluate the Safety and Efficacy of MANP in Subjects With Difficult to Control/ Resistant Hypertension". This is a Phase 2 dose-titration study designed to evaluate the safety and efficacy of MANP subcutaneous injection compared to placebo in reducing baseline daytime systolic blood pressure (SBP), derived from 24-hour ambulatory blood pressure monitoring (ABPM), in subjects with hypertension who are t...

What is the current status of trial NCT06343298?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2024-11-17. Estimated completion is 2026-09-01.

What conditions does trial NCT06343298 study?

This clinical trial studies the following conditions: Difficult to Control Hypertension.

What interventions are being tested in trial NCT06343298?

The interventions under investigation include: MANP (DRUG), Placebo Matched control (OTHER).

Who is sponsoring clinical trial NCT06343298?

This trial is sponsored by E-Star BioTech, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06343298 being conducted?

This trial has 20 study locations across Arkansas, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.